{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', 'results of the HemoCue Hgb assessment during their pariticipation in the study. Subjects', 'should be provided with the understanding to also not obtain Hgb information from local', 'labs prior to study visits. Additionally, Investigators, site staff and participants will also', 'be blinded to some of the central laboratory results during the study.', '7.5.', 'Preparation/Handling/StoragelAccountability', 'No preparation of study treatment is required.', 'The investigator or designee must confirm appropriate temperature conditions', 'have been maintained during transit for all study treatment received and any', 'discrepancies are reported and resolved before use of the study treatment.', 'Only participants enrolled in the study may receive study treatment and only', 'authorized site staff may supply or administer study treatment. All study treatments', 'must be stored in a secure, environmentally controlled, and monitored (manual or', 'automated) area in accordance with the labelled storage conditions with access', 'limited to the investigator and authorized site staff.', 'The investigator, institution, or the head of the medical institution (where', 'applicable) is responsible for study treatment accountability, reconciliation, and', 'record maintenance (i.e., receipt, reconciliation, and final disposition records).', 'Further guidance and information for the final disposition of unused study', 'treatment are provided in the Study Reference Manual.', 'Under normal conditions of handling and administration, study treatment is not', 'expected to pose significant safety risks to site staff.', 'A Material Safety Data Sheet (MSDS)/equivalent document describing', 'occupational hazards and recommended handling precautions either will be', 'provided to the investigator, where this is required by local laws, or is available', 'upon request from GSK.', '7.6.', 'Treatment Compliance', 'Given participants self-administer study treatment(s) at home, compliance with blinded', 'study treatment will be assessed through querying the participant during the site visits', 'and documented in the source documents and eCRF. A record of the number of bottles', 'of study treatment and the number of tablets from each bottle dispensed to and taken by', 'each participant must be maintained and reconciled with study treatment and compliance', 'records. Treatment start and stop dates, including dates for treatment delays and/or', 'treatmentinteruptions will also be recorded in the eCRF.', '7.6.1.', 'Study Treatment Extended Interruption', 'Sites should contact GSK if a subject will be away temporarily from the research site for', '>5 weeks during their participation in the study, in order to discuss options for continuing', 'randomized treatment and completing study visits. Every effort must be made to continue', 'randomized treatment; however if a subject will be off the study treatment, sites should', '46']['2016N298481_0', 'CONFIDENTIAL', '205270', 'consult with GSK in order to determine if the subjects should be withdrawn from', 'treatment and brought in for a treatment discontinuation visit.', '7.7.', 'Standard of Care', \"During the study (from screening), investigators are expected to monitor the participant's\", 'overall clinical status to ensure standards of care are met to enable consistency of practice', 'with Kidney Disease Improving Global Outcomes [KDIGO, 2012]guidelines or local', 'equivalent (e.g, phosphate and albumin).', 'For this study, specific iron management criteria and a dose adjustment algorithm for', 'randomized treatment will apply. These were developed to reflect global clinical practice.', '7.7.1.', 'Iron Management Criteria', \"Investigators should make every effort to maintain participants' serum TSAT >15% and\", 'ferritin > 50 ng/mL from randomization (Day 1) to end of study. The investigator will', 'follow the iron management criteria from randomization (Day 1) through end of study for', 'all participants receiving study treatment.', 'Iron therapy will be administered, starting with oral iron, if ferritin is <50 ng/mL and/or', \"TSAT is <15%, to reestablish participant's screening (Week -4) iron parameters.\", 'Participants that are on oral iron at randomization may change their dose of oral iron in', 'order to maintain their TSAT and ferritin levels as stated above. IV iron can be', 'administered to participants who are intolerant to oral iron, otherwise IV iron should only', 'be administered to participants being evaluated for rescue criteria (Section 7.7.2), please', 'see the SRM for additional IV Iron administration requirements. Iron parameters will be', 'assessed at scheduled study visits outlined in the SoA. Iron therapy may be discontinued', 'once screening ferritin and TSAT levels are reached', 'Only results for ferritin and TSAT measured by Q2 (central lab) should be used to', 'inform if iron therapy is required.', '7.7.2.', 'Rescue Criteria', 'A rescue algorithm is provided to minimize participants having an inadequate response to', 'the treatment for their anemia for an extended period of time and to enable consistency in', 'the application of rescue therapy across the study. Details are provided in Table 7.', 'This rescue algorithm does not apply to participants with low Hgb as a result of an acute', 'or subacute event with an identifiable cause (e.g., GI bleed, blood loss due to surgery or', 'vascular access). In these cases, treatment should be directed to the specific cause and', 'randomized treatment will be continued at the current dose (unless Hgb is 13 g/dL', 'which requires a dose hold).', '47']\n\n###\n\n", "completion": "END"}